Abstract: A method for the targeted delivery of the active generic antiproliferative and anti-inflammatory agents gemcitabine, paclitaxel and/or curcumin preferentially or exclusively to antigen-presenting cells (APCs) of the immune system by means of encapsulation into a lipid-based nanocarrier, the CLR-TargoSphere, which is surface-labeled with a Fucose-derivative ligand that exclusively targets C-type lectin receptors (CLRs) on APCs to deliver the active agents intracellularly to myeloid dendritic cells (mDCs), circulating monocytes, macrophages, and tumor-associated macrophages (TAMs) as well as cytotoxic T lymphocytes (CTLs).